Market Overview

According to The Insight Partners, the global Latent TB Detection Market was valued at US$ 1.23 billion in 2021 and is projected to reach US$ 2.00 billion by 2031, registering a compound annual growth rate (CAGR) of 5.8% during the forecast period.

Latent tuberculosis testing is an important component of global tuberculosis prevention and control strategies. These diagnostic procedures help identify individuals carrying tuberculosis bacteria without showing symptoms of active disease. Early identification enables healthcare professionals to assess the risk of disease progression and recommend appropriate preventive treatment.

The market includes two major testing technologies: the Tuberculin Skin Test and Interferon-Gamma Release Assays. IGRAs are increasingly preferred in several clinical settings because they provide blood-based testing and offer advantages in specificity, particularly among individuals who have received the BCG vaccine. Growing government investments in TB screening, increasing diagnostic awareness, and improvements in laboratory testing capabilities are supporting market expansion.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00014239

Key Market Drivers and Emerging Trends

Increasing Global Burden of Tuberculosis

The rising prevalence of tuberculosis across different regions is a major factor driving the Latent Tuberculosis Infection Testing Market. Tuberculosis remains a significant public health concern, particularly in developing countries where limited healthcare accessibility, inadequate diagnostic infrastructure, and delayed disease identification can contribute to continued transmission.

Identifying latent tuberculosis infections is essential for preventing the progression of infection into active TB disease. Healthcare organizations are increasingly emphasizing screening programs for high-risk populations, including individuals with weakened immune systems and people with close exposure to tuberculosis patients. Consequently, growing awareness of preventive healthcare and the importance of early identification is increasing demand for reliable LTBI diagnostic solutions.

Government Initiatives to Promote Tuberculosis Detection

Government initiatives and national tuberculosis elimination programs are creating significant opportunities for market growth. Countries with a high TB burden are implementing screening campaigns, improving diagnostic infrastructure, and expanding access to testing and treatment services.

India's National Strategic Plan for Tuberculosis Elimination and other international public health initiatives demonstrate the increasing commitment to reducing tuberculosis incidence. In addition, healthcare authorities are strengthening screening recommendations for healthcare workers and vulnerable populations.

These initiatives are encouraging hospitals, diagnostic laboratories, and public healthcare institutions to adopt advanced tuberculosis testing technologies. Increasing funding for disease prevention, improved diagnostic accessibility, and public awareness campaigns are expected to support market development.

Advancements in Interferon-Gamma Release Assays (IGRAs)

Technological advancements in tuberculosis diagnostics are transforming the LTBI Testing Market. Interferon-Gamma Release Assays are gaining attention as an alternative to traditional tuberculin skin testing because they use blood samples to evaluate immune responses to tuberculosis-specific antigens.

These tests offer advantages such as reduced dependence on patient follow-up visits for result interpretation and improved specificity in certain populations. Continuous improvements in laboratory automation, diagnostic sensitivity, and testing efficiency are further supporting their adoption.

Manufacturers are focusing on developing innovative testing kits and diagnostic platforms that provide reliable results and improve laboratory workflows. The growing preference for advanced blood-based testing methods is expected to create additional opportunities for market participants.

Increasing Demand for Advanced Diagnostic Infrastructure

The expansion of healthcare infrastructure and growing investments in diagnostic laboratories are supporting the adoption of LTBI testing solutions. Hospitals, diagnostic centers, and specialized laboratories require accurate testing technologies to identify tuberculosis infections and support effective disease management.

Emerging economies are increasingly investing in laboratory facilities, diagnostic equipment, and healthcare screening programs. Additionally, the growing availability of advanced testing kits and improved laboratory capabilities is helping expand access to tuberculosis diagnostics.

The increasing focus on preventive healthcare, combined with efforts to strengthen infectious disease surveillance, is expected to contribute to the long-term development of the market.

Key Players Profiled by The Insight Partners Include:

• QIAGEN

• bioMérieux S.A.

• F. Hoffmann-La Roche Ltd.

• BD (Becton, Dickinson and Company)

• ARKRAY, Inc.

• Abbott

• Serum Institute of India Pvt. Ltd.

• Oxford Immunotec Ltd.

• Lionex GmbH

Market Segmentation

The Latent TB Detection Market is segmented by test and end user.

By Test

• Tuberculin Skin Test (TST)

• Interferon-Gamma Release Assay (IGRA)

By End User

• Hospitals

• Diagnostic Centers

• Laboratories

• Others

The Interferon-Gamma Release Assay segment held the largest market share in 2023 and is also anticipated to register the highest CAGR during the forecast period. Similarly, hospitals accounted for the largest end-user market share in 2023 and are expected to maintain strong growth.

Regional Outlook

The Latent TB Detection Market is geographically segmented into five major regions:

• North America: United States, Canada, and Mexico.

• Europe: United Kingdom, Germany, France, Russia, Italy, and the Rest of Europe.

• Asia Pacific: China, India, Japan, Australia, and the Rest of Asia Pacific.

• South and Central America: Brazil, Argentina, and the Rest of South and Central America.

• Middle East and Africa: South Africa, Saudi Arabia, UAE, and the Rest of Middle East and Africa.

Asia Pacific is expected to register the fastest growth in the global Latent TB Detection Market. The region's growth is supported by a high tuberculosis burden, increasing government initiatives, expanding diagnostic infrastructure, and growing adoption of advanced testing technologies. Countries such as India and China are strengthening tuberculosis screening and elimination programs to improve disease prevention and control.

North America represents an important market due to established healthcare infrastructure, increasing awareness of tuberculosis screening, and the availability of advanced diagnostic technologies. Government recommendations and investments in infectious disease prevention are also supporting demand for reliable LTBI testing solutions.

Europe, South and Central America, and the Middle East and Africa are also expected to contribute to market development through improvements in healthcare accessibility, diagnostic capabilities, and national tuberculosis control initiatives.

Future Outlook

The Latent Tuberculosis Infection Testing Market is expected to experience steady growth as governments and healthcare organizations strengthen efforts to prevent tuberculosis and improve early infection detection. The increasing importance of preventive screening, growing awareness of latent infections, and expanding availability of advanced diagnostic technologies will remain important market growth factors.

Interferon-Gamma Release Assays, innovative testing kits, automated laboratory platforms, and improved diagnostic technologies are expected to influence future market development. These advancements may improve testing efficiency, support accurate identification, and increase access to LTBI screening.

Furthermore, government-funded tuberculosis elimination programs, expanding diagnostic laboratory networks, and increasing investments in infectious disease management are likely to create new opportunities for manufacturers. Companies focusing on affordable testing solutions, diagnostic accuracy, technological innovation, and emerging-market expansion are expected to strengthen their competitive positions through 2031.

Related Reports –

Tuberculosis Diagnostics Market Size, Share, Trends, and Forecast

Infectious Disease Diagnostics Market Size, Share, and Growth Forecast

About Us

The Insight Partners, we provide comprehensive analysis and insights into market trends that empower businesses to make informed decisions. Our reports are designed to equip stakeholders with the necessary information to navigate the complexities of various industries, including healthcare, technology, and finance. We are dedicated to delivering high-quality research that enables our clients to achieve their strategic objectives.

Contact Us:
Contact Person: Ankit Mathur
E-mail: [email protected]
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish